ESMO HIGHLIGHTS 2024 – MELANOMA ROUNDTABLE DISCUSSION: PD-1 Updates
OR
Please enter your username or email address. You will receive an email message to log in.
Chapter selection available inside video player. Click here for outline.
00:10
LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase 2 ImmunoCobiVem trial
02:16
LBA46 Primary efficacy, safety, and survival data from the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial with RP1 combined with nivolumab
Chair
Dr. Teresa Petrella
Panelists
Dr. Marcus Butler
Dr. Caroline Robert